Experimental combo for head and neck cancer shows safety promise
NCT ID NCT02997332
First seen Mar 26, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy is safe for people with advanced head and neck cancer. The study enrolled 14 patients and aimed to find the best dose. The trial was stopped early, but results help guide future research on combining these treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.